文献速递瓣膜外科

二次阻断在完美退行性二尖瓣修复中的决策算法、安全性与结局

Second crossclamp to perfect degenerative mitral valve repair: Decision-making algorithm, safety, and outcomes.
PubMed 文献 · J Thorac Cardiovasc Surg · 2019-10-16

该研究纳入2011至2016年40例因退行性二尖瓣病变修复后残余反流接受二次体外循环阻断的患者,描述了决策算法与结局。二次修复后85%患者无反流,5年免于中度及以上反流为100%,结论认为二次阻断可有效处理残余反流且增量风险小。

要点

  • 残余反流>+1或轻度伴不利机制时采用二次阻断再修复。
  • 二次修复后85%患者无反流,5年免于中度及以上反流100%。
  • 二次阻断时间34±12分钟,增量风险小。

核心结论

  • 残余二尖瓣反流可通过二次体外循环阻断有效治疗,长期结局良好且增量风险小。

研究设计与样本

  • 回顾性研究,纳入2011年1月1日至2016年12月31日40例退行性二尖瓣病变修复后残余反流接受二次体外循环阻断的患者。

主要发现

  • 二次修复后34例(85%)无反流,4例(10%)微量反流,2例(5%)轻度反流。
  • 出院时13例(33%)无反流,23例(58%)微量反流,4例(10%)轻度反流。
  • 5年免于中度及以上二尖瓣反流为100%。
  • 中位体外循环总时间208.5分钟,首次阻断106分钟,二次阻断34±12分钟。
  • 中位ICU停留2天,住院8天。

关键数值与推荐

  • 二次体外循环阻断的超声标准为中度及以上二尖瓣反流或轻度反流伴不利机制。
  • 术后反流原因为技术或残余病变35例,收缩期前向运动5例。
  • 再修复技术包括裂隙关闭22例、直接缝合修复13例、ePTFE人工腱索成形9例。

临床怎么用

  • 对退行性二尖瓣修复后残余反流>+1或轻度伴不利机制者,可考虑二次阻断再修复以追求完美修复。

局限性

  • 样本量小(40例),为单中心回顾性研究,未设对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Residual mitral regurgitation reduces the efficacy of mitral repair and is associated with worse outcomes. We adopted a policy using a second bypass run for patients with residual mitral regurgitation (>+1) and described our decision-making algorithm and outcomes. METHODS: From January 1, 2011, to December 31, 2016, 40 patients with degenerative disease underwent a second bypass run to address residual mitral regurgitation. The echocardiographic criteria for a second bypass run was the presence of moderate or greater mitral regurgitation or mild mitral regurgitation with unfavorable mechanism. RESULTS: A second bypass run was used in 40 patients. The mean age was 57.3 ± 13.5 years (21-79 years), and 14 patients (35%) were asymptomatic. Residual mitral regurgitation was mild in 25 patients, moderate in 9 patients, and moderate/severe in 6 patients. The cause of postbypass mitral regurgitation was technical or residual pathology in 35 patients and systolic anterior motion in 5 patients. Re-repair techniques were cleft closure in 22 patients, primary suture repair in 13 patients, and expanded polytetrafluoroethylene chordoplasty in 9 patients. After re-repair, 34 patients (85%) had no mitral regurgitation, 4 patients (10%) had trace mitral regurgitation, and 2 patients (5%) had mild mitral regurgitation. Median total cardiopulmonary bypass time was 208.5 minutes, first crossclamp time was 106 minutes, and second crossclamp time was 34 ± 12 minutes. Median intensive care stay was 2 days, and hospital stay was 8 days. On discharge, there was no mitral regurgitation in 13 patients (33%), trace in 23 patients (58%), and mild mitral regurgitation in 4 patients (10%). Freedom from moderate or greater mitral regurgitation at 5 years was 100%. CONCLUSIONS: Residual mitral regurgitation can be effectively treated using a second bypass run with good long-term outcome and minimal incremental risk.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. El-Eshmawi A, Anyanwu A, Boateng P, et al. Second crossclamp to perfect degenerative mitral valve repair: Decision-making algorithm, safety, and outcomes. J Thorac Cardiovasc Surg. 2019. PMID: 31810650. doi:10.1016/j.jtcvs.2019.09.149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。